Search results
Results From The WOW.Com Content Network
In the right context, “psychedelics can get the brain out of a state of depression or anxiety, a cycle of negative thoughts, self-perception, moods and behaviors,” Siegel said.
[27] In 1968, Dahlberg and colleagues published an article in the American Journal of Psychiatry detailing various forces that had successfully discredited legitimate LSD research. [28] The essay argues that individuals in government and the pharmaceutical industry sabotaged the psychedelic research community by canceling ongoing studies and ...
The Journal of Psychoactive Drugs is a peer-reviewed medical journal on psychoactive drugs. It was established in 1967 by David E. Smith and is currently published five times per year by Taylor & Francis. It was previously titled Journal of Psychedelic Drugs until 1980.
In 2004, however, White retracted the article in which he made these claims. [24] A formal survey of dextromethorphan users [25] showed that more than half of users reported experience of these withdrawal symptoms individually for the first week after long-term/addictive dextromethorphan use: fatigue, apathy, flashbacks, and constipation. Over ...
[22] [23] [24] His research has also compared the effectiveness of psychedelic drugs against conventional SSRI drug treatments for depression. [25] [26] Carhart-Harris believes psychedelics could be useful in treating other mental disorders, such as addiction and obsessive–compulsive disorder (OCD), [27] as well as potentially enhancing ...
Psilocybin-containing mushrooms. Psilocybin therapy is the use of psilocybin (the psychoactive ingredient in psilocybin mushrooms) in treating a range of mental health conditions, such as depression, anxiety, addictions, [1] obsessive compulsive disorder (OCD), and psychosis. [2]
Hallucinogen persisting perception disorder (HPPD) is a non-psychotic disorder in which a person experiences apparent lasting or persistent visual hallucinations or perceptual distortions after using drugs, [1] including but not limited to psychedelics, dissociatives, entactogens, tetrahydrocannabinol (THC), and SSRIs.
In the early 1960s in Psychedelic Research Institute in Prague, Czechoslovakia, Stanislav Grof tested the value of LSD in treatment of psychologically ill patients. His goal was to observe the effect of psychedelics on the psychology of terminally-ill cancer patients. [3] Grof would later be involved in research at the Spring Grove Clinic.